1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Stem Cell Global Market Report 2021: COVID-19 Growth And Change To 2030

Stem Cell Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021
  • 175 pages
  • ID: 6151607
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the stem cell market are Anterogen Co. Ltd, Mesoblast Ltd, Osiris Therapeutics Inc, AlloSource, and Cellular Engineering Technologies.

The global stem cell market is expected to grow from $20.59 billion in 2020 to $22.87 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $36 billion in 2025 at a CAGR of 12%.

The stem cell market consist of sales of stem cells products such as human embryonic stem cell, induced pluripotent stem cell and adult stem cell.Stem cells are the autologous or allogenic cells that can grow into many types of cells in in-vivo and in-vitro environment.

Stem cells therapy is designed to aid physician in performing medical treatment of neurodegenerative diseases, diabetes and heart disease.

The stem cell market covered in this report is segmented by source into autologous, allogeneic. It is also segmented by product type into adult stem cell, human embryonic stem cell, induced pluripotent stem cell, others and by application into regenerative medicine, drug discovery and development.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The low acceptance rate for stem cell therapy treatments is restraining the growth of the stem cell market.The acceptance rate is particularly low in the Embryonic stem cell therapeutics.

Most of these stem cell therapies are yet to be proven in clinical trials and are highly experimental.Due to the nature of these unproven treatments, patients are reluctant to take up these therapies as they present serious health, personal and financial issues.

For example, if a person undergoes an unproven or experimental treatment it might make that person ineligible for future clinical trials or treatment options. For instance, in USA,, an unproven stem cell offering three elderly women were blinded after getting stem cells derived from fat tissue, at a clinic in Florida These factors are limiting the number of people opting for stem cell therapies, thus restraining the growth of the market.

Companies in the stem cell therapeutics market are focusing on development of new technologies such as the Induced Pluripotent Stem Cells (IPSC) to boost the efficiency of stem cell therapies.IPSC are obtained from blood or skin cells that are reprogrammed to an embryonic-like pluripotent state by incorporating genes that are essential for maintaining key properties and growth of an unlimited source of any kind of human cell required for stem cell therapeutic purposes.

These IPSC’s are not derived from human embryos, which removes the bioethical issues, thus allowing scientists to obtain federal funding and support easily.A Japanese company, Oksara opened a medicine center that produced cells derived from iPS Cells.

Similarly, Takar Bio company launched human iPSC derived Beta Cells i.e., Cellartis® for disease modeling and drug discovery.

Celgene Corporation acquired Juno Therapeutics in March 2018, for $9 Billion.With this acquisition, Celgene will be positioned to become a leader in cellular immunotherapy.

It is expected that with the addition of Juno’s JCAR017 therapy to their portfolio and other cellular immunotherapy products in Juno’s pipeline, Celgene would accelerate its revenue diversification. Juno Therapeutics, founded in 2013, is a Seattle-based biotech company which is into cutting-edge cancer immunotherapy treatments.

There is an increase in the prevalence of Chronic diseases worldwide which drives the Stem cell market.Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition.

Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.Currently, widely used stem cell treatment is the transplantation of blood stem cells to treat diseases and conditions of the blood and immune system, or to restore the blood system after treatments for specific cancers.

According to WHO, by 2020, prevalence of chronic disease is predicted to increase by 57%.As the prevalence of chronic disease increases, people opting for the stem cell-based treatment will rise, thus driving the market going forward.

Currently, approximately 26,000 patients are treated with blood stem cells in Europe each year.

The Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) is the regulator in the US, for human cells, tissues, and cellular and tissue-based products (HCT/P) intended for implantation, transplantation, infusion or transfer into a human recipient, including hematopoietic stem cells.There are certain protocols that the FDA has established, for example, the current good tissue practice, donor screening and donor testing requirements which are in place to prevent the transmission of any communicable diseases.

The stem cells come from different sources (bone marrow, umbilical cord blood or peripheral blood) and have different applications. Licenses are required to distribute and market these products.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Zinc Finger Nuclease Technology Market Research Report by Type, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 188 pages

Zinc Finger Nuclease Technology Market Research Report by Type (Animal Genetic Engineering, Cell Line Engineering, and Plant Genetic Engineering), by Application (Academic and Research Institutes, Biotechnology ...

  • World
  • Biotechnology
  • Laboratory
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on